FLT3 and acute myeloid leukemia: Notably, addition of midostaurin to induction chemotherapy resulted in a 22% reduction in the risk of death compared to placebo in patients younger than 60 years of age with fms-related tyrosine kinase 3 gene (FLT3) mutated AML (6).